Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Business Insider6d
Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England
Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy. The ...
Business Insider6d
Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at ...
The Patriot Ledger6d
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...
Benzinga.com6d
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Get the Real Story Behind Every Major Earnings Report Vertex Pharmaceuticals Inc. VRTX shares are trading higher Friday following two major developments that strengthen its position in both pain ...
Investopedia6d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...
Fox Business6d
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...
MarketWatch6d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...
Benzinga.com7d
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 21 analysts. Summarizing their recent assessments, the table below illustrates ...
Yahoo Finance9d
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile ...
Wall Street Journal7d
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals VRTX5.31%increase ... received Food and Drug Administration approval. The Boston company’s stock rose 4.3%, to $457.25, after hours Thursday.
Yahoo Finance6d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the ...